Evaluation of clinical outcomes in patients treated with heparin or direct thrombin inhibitors during extracorporeal membrane oxygenation: a systematic review and meta-analysis.
Anticoagulation
Argatroban
Bivalirudin
Bleeding
Mechanical circulatory support
Thrombosis
Journal
Thrombosis journal
ISSN: 1477-9560
Titre abrégé: Thromb J
Pays: England
ID NLM: 101170542
Informations de publication
Date de publication:
28 Jul 2022
28 Jul 2022
Historique:
received:
12
05
2022
accepted:
15
07
2022
entrez:
28
7
2022
pubmed:
29
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
The number of patients treated with extracorporeal membrane oxygenation (ECMO) devices is increasing. Anticoagulation therapy is crucial to prevent thrombosis during ECMO therapy. Predominantly, heparin has been used as primary anticoagulant but direct thrombin inhibitors (DTI) have been established as alternatives. The aim of this systematic review and meta-analysis was to evaluate clinical outcomes in patients treated with heparin compared to different DTI during ECMO. A systematic search was conducted. Full scientific articles were sought for inclusion if heparin anticoagulation was compared to DTI (argatroban/bivalirudin) in ECMO patients. Risk of bias was assessed by Newcastle Ottawa scale. Primary endpoint was in-hospital mortality. Bleeding events, thrombotic events, hours of ECMO support, days of hospital stay, percentage of time within therapeutic range and time to therapeutic range were extracted from full texts as secondary endpoints. Results were presented as Forrest-plots. GRADE was used for confidence assessment in outcomes. Systematic search identified 4.385 records, thereof 18 retrospective studies for a total of 1942 patients, complied with the predefined eligibility criteria:15 studies investigated bivalirudin and 3 studies investigated argatroban versus heparin. Risk of bias was high for most studies. In-hospital mortality, major bleeding events and pump-related thrombosis were less frequent in DTI group as compared to heparin [mortality-OR 0.69, 95% CI 0.54-0.86; major bleeding-OR 0.48, 95% CI 0.29-0.81; pump thrombosis-OR 0.55, 95% CI 0.40-0.76]. Additionally, percentage of time within therapeutic range was higher for DTI [SMD 0.54, 95% CI 0.14-0.94]. GRADE approach revealed a very low level of certainty for each outcome. In this meta-analysis, DTI and especially bivalirudin showed beneficial effects on clinical outcomes in ECMO patients as compared to heparin. However, due to the lack of randomized trials, certainty of evidence is low. This systematic review and meta-analysis was prospectively registered at PROSPERO data base (reference number CRD42021237252 ).
Sections du résumé
BACKGROUND
BACKGROUND
The number of patients treated with extracorporeal membrane oxygenation (ECMO) devices is increasing. Anticoagulation therapy is crucial to prevent thrombosis during ECMO therapy. Predominantly, heparin has been used as primary anticoagulant but direct thrombin inhibitors (DTI) have been established as alternatives. The aim of this systematic review and meta-analysis was to evaluate clinical outcomes in patients treated with heparin compared to different DTI during ECMO.
METHODS
METHODS
A systematic search was conducted. Full scientific articles were sought for inclusion if heparin anticoagulation was compared to DTI (argatroban/bivalirudin) in ECMO patients. Risk of bias was assessed by Newcastle Ottawa scale. Primary endpoint was in-hospital mortality. Bleeding events, thrombotic events, hours of ECMO support, days of hospital stay, percentage of time within therapeutic range and time to therapeutic range were extracted from full texts as secondary endpoints. Results were presented as Forrest-plots. GRADE was used for confidence assessment in outcomes.
RESULTS
RESULTS
Systematic search identified 4.385 records, thereof 18 retrospective studies for a total of 1942 patients, complied with the predefined eligibility criteria:15 studies investigated bivalirudin and 3 studies investigated argatroban versus heparin. Risk of bias was high for most studies. In-hospital mortality, major bleeding events and pump-related thrombosis were less frequent in DTI group as compared to heparin [mortality-OR 0.69, 95% CI 0.54-0.86; major bleeding-OR 0.48, 95% CI 0.29-0.81; pump thrombosis-OR 0.55, 95% CI 0.40-0.76]. Additionally, percentage of time within therapeutic range was higher for DTI [SMD 0.54, 95% CI 0.14-0.94]. GRADE approach revealed a very low level of certainty for each outcome.
CONCLUSION
CONCLUSIONS
In this meta-analysis, DTI and especially bivalirudin showed beneficial effects on clinical outcomes in ECMO patients as compared to heparin. However, due to the lack of randomized trials, certainty of evidence is low.
TRIAL REGISTRATION
BACKGROUND
This systematic review and meta-analysis was prospectively registered at PROSPERO data base (reference number CRD42021237252 ).
Identifiants
pubmed: 35902857
doi: 10.1186/s12959-022-00401-2
pii: 10.1186/s12959-022-00401-2
pmc: PMC9330661
doi:
Types de publication
Journal Article
Langues
eng
Pagination
42Informations de copyright
© 2022. The Author(s).
Références
ASAIO J. 2021 Jun 1;67(6):688-696
pubmed: 33031157
J Card Surg. 2020 Apr;35(4):779-786
pubmed: 32048330
Br J Clin Pharmacol. 2022 Jun;88(6):2605-2616
pubmed: 35098565
J Thorac Dis. 2019 Aug;11(8):3325-3335
pubmed: 31559035
Thromb Res. 2023 Sep;229:178-186
pubmed: 37517208
J Intensive Care Med. 2022 Apr;37(4):459-471
pubmed: 33653194
J Thromb Haemost. 2019 Oct;17(10):1608-1622
pubmed: 31313454
Transfus Med Rev. 2015 Apr;29(2):90-101
pubmed: 25595476
Crit Care Explor. 2021 Sep 07;3(9):e0530
pubmed: 34514426
Pediatr Crit Care Med. 2020 Nov;21(11):975-985
pubmed: 32976347
Perfusion. 2023 Jan;38(1):58-65
pubmed: 34318718
Ann Cardiothorac Surg. 2019 Jan;8(1):19-31
pubmed: 30854309
Hosp Pharm. 2021 Aug;56(4):276-281
pubmed: 34381261
Crit Care. 2021 Apr 29;25(1):160
pubmed: 33910609
Thromb Res. 2022 Feb;210:53-62
pubmed: 35007937
Crit Care Med. 2021 Jul 1;49(7):1129-1136
pubmed: 33711003
J Korean Med Sci. 2011 Jul;26(7):945-50
pubmed: 21738350
Korean J Thorac Cardiovasc Surg. 2018 Apr;51(2):114-121
pubmed: 29662809
ASAIO J. 2022 Jul 1;68(7):920-924
pubmed: 34669620
Anaesth Crit Care Pain Med. 2018 Jun;37(3):259-268
pubmed: 29033360
Crit Care Explor. 2021 Jul 13;3(7):e0485
pubmed: 34278315
Interact Cardiovasc Thorac Surg. 2017 Dec 1;25(6):898-904
pubmed: 29049666
Ann Intensive Care. 2017 Dec;7(1):82
pubmed: 28776204
Ann Thorac Surg. 2016 Aug;102(2):534-9
pubmed: 27083248
J Cardiothorac Vasc Anesth. 2022 Jun;36(6):1703-1708
pubmed: 34686438
Artif Organs. 2021 Jan;45(1):15-21
pubmed: 32557733
Thromb Res. 2022 Mar;211:154-160
pubmed: 35180657
ASAIO J. 2018 Sep/Oct;64(5):623-629
pubmed: 29076942
Perfusion. 2019 Nov;34(8):671-678
pubmed: 31057056
Pharmacol Res. 2022 Mar;177:106089
pubmed: 35065202
ASAIO J. 2021 Jun 1;67(6):601-610
pubmed: 33965970
Crit Care. 2011;15(6):R275
pubmed: 22099212
J Cardiothorac Vasc Anesth. 2013 Feb;27(1):30-4
pubmed: 23036625
Crit Care Med. 2021 Sep 1;49(9):1481-1492
pubmed: 33870916
Pediatr Crit Care Med. 2020 Sep;21(9):827-834
pubmed: 32404633
J Thorac Dis. 2019 Jul;11(7):2861-2867
pubmed: 31463115
Crit Care. 2019 Jun 14;23(Suppl 1):203
pubmed: 31200746